FibroBiologics Appoints Leigh Steinberg to Board as Class II Director

What Happened
FibroBiologics, Inc. (FBLG) announced on Form 8-K (filed Aug 24, 2026) that its Board appointed Leigh Steinberg as a Class II director effective August 20, 2026. Mr. Steinberg will serve until the expiration of his term at the company’s 2028 annual meeting. He will receive the same compensation as other non-employee directors under the company’s Non-Employee Director Compensation Policy, and the company entered into its standard form of indemnification agreement with him.

Key Details

• Appointment effective: August 20, 2026.
• Term: Class II director through the 2028 annual meeting of stockholders.
• Compensation: Entitled to standard non-employee director compensation under the Company’s policy.
• Governance/agreements: Company executed its standard indemnification agreement with Mr. Steinberg; no related-party transactions or arrangements requiring disclosure under Item 404(a) of Regulation S-K.
• Disclosure: Press release announcing the appointment furnished as Exhibit 99.1 to the Form 8-K.

Why It Matters
This is a board-level personnel change that may affect company governance and oversight. The filing indicates the appointment follows the company’s standard director compensation and indemnification practices and that no related-party relationships were reported, suggesting a routine, independent addition to the board. There is no immediate financial impact disclosed; investors should note the change for governance tracking and look for any future disclosures about strategic roles or committee assignments that could affect company direction.